Robyn Karnauskas

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) jumped over 14 percent on Friday, as a buyout rumor surfaced just ahead of an apparently routine conference call with analysts concerning its developmental drug programs. Separately, Deutsche Bank's Robyn Karnauskas published a note on Friday...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is getting insufficient credit from investors for its development pipeline, an analyst said Wednesday. The company's sole commercial product, Soliris, is approved for treating two rare blood disorders and produced sales last year of about $2.23...

AbbVie Inc (NYSE: ABBV) $21 billion deal to acquire Pharmacyclics, Inc. (NASDAQ: PCYC) Thursday drew mixed reviews from analysts and a thumbs down in the stock market. Shares of AbbVie closed down more than 5 percent at $56.83. The price paid by AbbVie may be a sign of a "desperation...

Deutsche Bank commented on AbbVie Inc (NYSE: ABBV) and Gilead Sciences, Inc. (NASDAQ: GILD) Wednesday and felt that consensus may be too high on both companies. Analyst Robyn Karnauskas commented that "the key question we are getting from investors is if ABBV 2015 consensus is too high for...

Gilead Sciences, Inc. (NASDAQ: GILD) may continue to dominate the market for hepatitis C drugs but growing competition will result in lower prices, an analyst said Tuesday. Gilead fell sharply on Monday after Express Scripts Holding Company (NASDAQ: ESRX), a giant pharmacy benefits manager,...

Deutsche Bank issued an analyst note on Biogen Idec Inc (NASDAQ: BIIB) after the company reported positive data for BIIB-037 in Alzheimer’s at the firm’s biofest. Analyst Robyn Karnauskas commented, “The company noted that they saw dose and time dependent reductions in Amyloid...

On Friday, Deutsche Bank analysts initiated coverage on shares of AbbVie Inc (NYSE: ABBV) with a Buy rating and $80 price target. Robyn Karnauskas outlined reasons for the Buy rating: 2015 HCV estimates are too low. HCV revenues will offset lost sales. AbbVie’s HCV pipeline is...

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target from $190.00 to $192.00. In the report, Deutsche Bank noted, “85.1% of pts in the high-dose arm and 69.2% of pts in the low dose arm achieved PASI75...

In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Celgene Corporation (NASDAQ: CELG), and raised the price target from $115.00 to $134.00. In the report, Deutsche Bank noted, “The focus of the 3Q call was the strong Otezla launch, and the pipeline,...

Deutsche Bank issued an alert on Gilead Sciences, Inc. (NASDAQ: GILD) Tuesday following news about Irish tax changes and Johnson & Johnson (NYSE: JNJ) comments. The alert concluded that Tuesday’s "stock reaction is overdone." According to analyst Robyn Karnauskas, "...

Arrowhead Research Corp (NASDAQ: ARWR) had its price target lowered from $45 to $20 by Deutsche Bank on Wednesday. The firm maintained a Buy rating. The report stated, "we see higher risk but do not think the program is dead." The stock fell approximately 50 percent Wednesday due to...

Robyn Karnauskas of Deutsche Bank spoke on CNBC's Fast Money about stocks she likes in the biotech space. She said that the sector has above average growth, three percent more than the S&P 500, and the group is trading only with a small premium over the S&P. Karnauskas is bullish on the...

Achillion Pharmaceuticals (NASDAQ: ACHN) and Arrowhead Research (NASDAQ: ARWR) were up sharply Tuesday after an analyst said the pair of drug development companies could become takeover targets. "If you want to compete with Gilead, you have to buy Achillion," Deutsche Bank's Robyn...

Regado Biosciences (NASDAQ: RGDO) plunged after safety concerns permanently halted trials on its lead drug candidate for preventing complications from angioplasty surgery. Deutsche Bank's Robyn Karnauskas downgraded the shares to Hold from Buy and slashed her target 87 percent to $2, from $14....

Shares of Sarepta Therapeurics (NASDAQ: SRPT) plummeted 28.2 percent Thursday morning following the long-term outcomes from the Phase IIb study of Eteplirsen. Deutsche Bank analyst Robyn Karnauskas maintained a Hold rating on shares, as the firm waits for more information on the upcoming biopsy...